Palvella Therapeutics (NASDAQ:PVLA) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by Stifel Nicolaus from $60.00 to $80.00 in a research report report published on Wednesday, MarketBeat reports. The brokerage currently has a buy rating on the stock.

A number of other analysts have also recently weighed in on the stock. Oppenheimer began coverage on shares of Palvella Therapeutics in a report on Tuesday, September 9th. They issued an “outperform” rating and a $85.00 price objective on the stock. Truist Financial began coverage on shares of Palvella Therapeutics in a report on Monday, July 21st. They issued a “buy” rating and a $56.00 price objective on the stock. Canaccord Genuity Group increased their price objective on shares of Palvella Therapeutics from $52.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, August 19th. Raymond James Financial set a $54.00 price objective on shares of Palvella Therapeutics and gave the stock an “outperform” rating in a report on Tuesday, August 5th. Finally, Lifesci Capital assumed coverage on shares of Palvella Therapeutics in a research note on Monday, August 4th. They set an “outperform” rating and a $90.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the stock. Based on data from MarketBeat.com, Palvella Therapeutics currently has a consensus rating of “Buy” and an average price target of $67.09.

Palvella Therapeutics Stock Performance

Shares of NASDAQ:PVLA opened at $59.59 on Wednesday. The stock has a market capitalization of $659.07 million, a price-to-earnings ratio of -4.92 and a beta of -0.03. Palvella Therapeutics has a 1-year low of $11.17 and a 1-year high of $63.12. The company’s fifty day moving average is $48.78 and its two-hundred day moving average is $32.85.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). Sell-side analysts expect that Palvella Therapeutics will post -3.69 EPS for the current fiscal year.

Hedge Funds Weigh In On Palvella Therapeutics

Several large investors have recently made changes to their positions in PVLA. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Palvella Therapeutics during the 2nd quarter valued at about $37,000. Spire Wealth Management acquired a new position in shares of Palvella Therapeutics in the first quarter worth about $70,000. JPMorgan Chase & Co. boosted its holdings in shares of Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after buying an additional 3,242 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Palvella Therapeutics in the second quarter worth about $85,000. Finally, BNP Paribas Financial Markets acquired a new position in shares of Palvella Therapeutics in the second quarter worth about $104,000. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.